杉木SHANMU获数千万Pre-A+融资 加速AI家庭医疗机器人落地

Group 1 - Shanmu (Shenzhen) Biotechnology Co., Ltd. has completed a new round of financing worth tens of millions in Pre-A+ round, aimed at optimizing shareholder structure and accelerating the deployment of its "AI home medical robot" [1][10] - The investment round includes prominent figures from academia and industry, forming a "professor team" that enhances the credibility and influence of the investment [3][7] - The core product of Shanmu, the "Perception Series," is the world's smallest automated medical robot, capable of performing comprehensive biochemical analysis at home, thus revolutionizing traditional medical practices [9][10] Group 2 - The financing is seen as a recognition of Shanmu's technological strength and highlights the potential of the "AI + home healthcare" sector, especially in the context of an aging population and increasing health management needs [10] - Shanmu's model combines miniaturized devices, AI diagnostics, and full-cycle management, positioning it as a key player in the family healthcare market, which is projected to be worth hundreds of billions [10]